|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.33 USD | +4.88% |
|
-2.16% | +27.28% |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,815 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 29.38% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 3,193 | 3,555 | 3,435 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 54.53% | 11.34% | -3.39% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -8.25x | -8.99x | -10.5x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 20.1x | -18.5x | 20x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.7x | 1.09x | 0.7x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 44.8x | 41x | 22.7x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 37.5x | 38.2x | 20.5x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -6.76x | -7.82x | -12x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -6.48x | -7.36x | -7.41x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -12.4x | -10.7x | -18x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -8.09% | -9.38% | -5.54% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.675 | -3.372 | -2.885 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 85.06 | 93.06 | 167.8 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -472.1 | -454.5 | -285.6 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -492.6 | -483.2 | -463.6 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -456.4 | -430.5 | -394.5 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -621.3 | -259.3 | -379.9 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 30.33 | 30.33 | 30.33 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 125,773 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 2/21/24 | 2/25/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.25x | 37.54x | -6.76x | -.--% | 3.81B | |
| 34.6x | 6.07x | 18.79x | 0.95% | 49.92B | |
| -23.69x | 348.89x | -22.4x | -.--% | 40.23B | |
| 25.19x | 2.79x | 12.06x | -.--% | 34.55B | |
| 44.97x | 4.49x | 28.67x | -.--% | 33.09B | |
| 30.52x | 8.33x | 21.46x | 0.41% | 27.51B | |
| 32.72x | 5.32x | 24.23x | -.--% | 15.92B | |
| 24.09x | 2.05x | 9x | 1.11% | 13.86B | |
| -22.69x | 14.88x | -22.26x | -.--% | 13.52B | |
| Average | 15.27x | 47.82x | 6.98x | 0.27% | 25.83B | |
| Weighted average by Cap. | 19.31x | 65.70x | 9.36x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
